PLGA-PEG | Nanoprecipitation | Docetaxel | - | LNCaP | 80-200 | - | [123] |
PLGA-PEG | Nanoprecipitation | Cisplatin | - | LNCaP, PC3 | (131 ± 0.5) - (172 ± 3.4) | - | [124] |
PLGA-PEG | Emulsion-solvent evaporation | Conjugated peptide, Coumarin-6 | - | bEnd.3 | (104.17 ± 3.45) - (121.46 ± 0.76) | (−24.43 ± 0.22) - (−18.25 ± 0.88) | [125] |
PLGA-PEG | Modified double emulsion | Cisplatin | Sodium Cholate | LNCaP | (134.3 ± 5.2) - (159.8 ± 6.2) | (−5.7) - (−9.3) | [126] |
PLGA-PEG | Solvent-diffusion | Doxorubicin | PEMA | MDA-MB-231, B16F10, MCF-7 | (366.6 ± 3.1) - (423.0 ± 16.6) | (−18.9 ± 2.4) - (−51.7 ± 3.1) | [127] |
PLGA-PEG | Nanoprecipitation | Paclitaxel | - | HUVEC | (114 ± 3) - (146 ± 2) | (−0.36 ± 4.3) - (0.12 ± 3.6) | [128] |
PLGA-PEG | Solvent evaporation | Paclitaxel | PVA | JC, NCI/ ADR-RES or MCF-7 | (221 ± 5) - (240 ± 1) | (−18 ± 5) - (−35 ± 5) | [129] |
PLGA-PEG | Nanoprecipitation | Docetaxel | - | LNCaP | (153.3 ± 13.9) | −42 ± 1 | [130] |
PLGA?PEG | Emulsion-solvent diffusion | Docetaxel | PVA | SKOV3 | (120 ± 5) - (216 ± 18) | (−6.27 ± 0.95) - (−12.2 ± 0.6) | [131] |
PLGA-PEG-Aptamer | Nanoprecipitation | Docetaxel | - | LNCaP, PC3 | (160 ± 3.7) - (291 ± 5.2) | (−20) - (−29) | [132] |
PLGA-PEI | Solvent displacement | Plasmid DNA | Poloxamer-188 | Calu-3 | 207 - 231 | (32.1 ± 6.7) - (58.8 ± 4) | [133] |
PLGA-PEI | Solvent evaporation | Paclitaxel | PVA | JC | (228 ± 22) - (237 ± 16) | (−12.1 ± 0.3) - (−24.0 ± 0.5) | [134] |
PLGA-TPGS | Solvent extraction/ evaporation | Docetaxel | TPGS | Caco-2, MCF-7 | (219.42 ± 5.24) - (253.51 ± 5.38 | (−21.87 ± 2.11) - (34.1 ± 4.28) | [135] |
PLGA-TPGS | Solvent extraction/ evaporation | Doxorubicin | - | MCF-7, C6 glioma | (324 ± 5) - (359 ± 10) | - | [136] |
PLGA-TPGS) | Modified solvent extraction/ evaporation | Docetaxel, Coumarin-6 | TPGS | HeLa | (207.15 ± 8.46) - (290.25 ± 7.64) | (−15.22 ± 2.21) - (−32.10 ± 0.65) | [137] |
PMB, PMBH | Emulsion-solvent evaporation | Doxorubicin, Paclitaxel | - | HeLa | 242 ± 10, 218 ± 9 | −2.0 ± 0.5, −2.0 ± 0.6 | [138] |
Poly (ethylene oxide)- modified poly (beta-amino ester) | Solvent evaporation | Paclitaxel, | - | SKOV-3 | 60 - 150 | 40 | [139] |
Poly (β-amino esters) {Arg-Gly-Asp (RGD) peptide coated} | Electrostatic self-assembly | DNA | - | HUVEC | 200 | −5 | [140] |
Poly (β-malic acid) | - | Antisense oligonucleotides | - | U87MG, TG98, MDA MB-231. | 6.6 - 24 | (−27 ± 1) - (−5.2 ± 0.4) | [141] |
Poly (β-malic acid) | - | Antisense oligonucleotides | - | BT-474, SKBR-3, MDA-MB-231, MDA- MB-435, MDA-MB-468, MCF-7 | (15.1 ± 1.2) - (22.1 ± 2.3) | (−4.1 ± 0.4) - (−5.7 ± 0.6) | [142] |
Poly (γ-glutamic acid)-Poly (lactide) | Emulsion-solvent evaporation | Paclitaxel | - | HepG2 | (115.4 ± 4.2) - (263.2 ± 6.8) | (−19.2 ± 2.2) - (−22.5 ± 3.2) | [143] |
PS (Carboxyl- modified fluorescent) | Commercial | - | Commercial | HeLa, HUVEC | 24 ± 4, 43 ± 6 | - | [25] [144] |
β-Cyclodextrin (Transferrin conjugated) | Polycondensation | DNA | - | PC-3, K562 | 100 - 150 | 15 | [145] |